Albemarle (ALB) Sees 1% Price Movement on Lower Than Average Volume

This morning we watched Albemarle rise 1.0% to a price of $241.5 per share. The large-cap Chemicals company is now trading -8.17% below its average target price of $262.98. Analysts have set target prices ranging from $155.0 to $360.0 per share for Albemarle, and have given the stock an average rating of buy.

The stock has an average amount of shares sold short at 6.4%, and a short ratio of 3.34. The company's insiders own 0.22% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 87.1% of Albemarle's shares being owned by this investor type.

Institutions Invested in Albemarle

Date Reported Holder Percentage Shares Value
2023-03-31 Vanguard Group, Inc. (The) 12% 14,204,830 $3,430,466,445
2023-03-31 Blackrock Inc. 8% 9,582,008 $2,314,054,932
2023-03-31 Capital International Investors 8% 9,450,054 $2,282,188,041
2023-03-31 State Street Corporation 4% 5,024,760 $1,213,479,540
2023-03-31 FMR, LLC 3% 3,026,254 $730,840,341
2023-03-31 Franklin Resources, Inc. 2% 2,731,009 $659,538,673
2023-03-31 Baillie Gifford and Company 2% 2,540,607 $613,556,590
2023-03-31 Capital Research Global Investors 2% 2,527,685 $610,435,927
2023-03-31 Geode Capital Management, LLC 2% 2,422,227 $584,967,820
2023-03-31 Bank of America Corporation 2% 2,043,164 $493,424,106

Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on Albemarle.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.